Objective: Concurrent chemoradiotherapy (CRT) was the standard treatment for locally advanced NSCLC (LA-NSCLC). This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on adverse events (AEs).
significantly fewer grade 4 or higher AEs than ENI TRT. This is likely the result of irradiation of a lesser amount of adjacent critical normal tissue. Higher TRT doses were associated significantly with grade 3 or higher and grade 4 or higher AEs. On the basis of these findings and our prior report on survival, CRT using IF-TRT and 60 Gy (conventionally fractionated) were associated with more favorable patient survival and less toxicity than was the use of ENI or higher radiotherapy doses.
Introduction
Important controversies remain in the treating locally advanced (LA) NSCLC (LA-NSCLC). Basic questions related to radiotherapy (RT) have not been answered: what dose-fractionation pattern is best? and should thoracic RT (TRT) target only radiographically visible disease with involved-field (IF) TRT (IF-TRT), or should it also target the adjacent lymph nodes that are radiographically normal with elective nodal irradiation (ENI)? To address these questions, we performed a pooled analysis. The first goal of the analysis was to establish which RT strategies were associated with survival. 1 IF-TRT was associated with significantly better survival than ENI was, and doses higher than 60 Gy were not associated with better survival than 60 Gy was. 1 We hypothesized that ENI and higher doses of TRT were associated with toxicity and performed this analysis.
Methods and Materials
This pooled analysis included 3600 patients with LA-NSCLC who had participated in 16 chemoradiotherapy (CRT) trials. These trials and patient characteristics were summarized in our previous survival analysis. 1 The cooperative groups provided individual patient data for patients with unresectable LA-NSCLC who participated in concurrent CRT trials . 1 The goal was to identify associations between adverse events (AEs) and both TRT dose and targeting strategies. The primary end point of this analysis was the occurrence of AEs, as determined by use of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). The RT variables evaluated included nodal coverage strategy (IF-TRT versus ENI TRT) and total TRT dose (60 Gy versus >60 Gy). IF-TRT generally included targeting of the primary lesion and regional lymph nodes measuring more than 1 cm in the short diameter and those that were hypermetabolic on positron emission tomography (PET). ENI generally included IF-TRT plus regional lymph nodes that were radiographically normal.
Statistical Analysis
The associations between TRT and other patient characteristics were evaluated with the chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables. The associations between radiation parameters as categorical variables and the occurrence of AEs were examined by using the chi-square test. The analyses evaluating the associations between AEs and radiation parameters were performed with univariable and multivariable logistic regression models; the ORs and corresponding confidence intervals (CIs) were reported. p Values were two sided and were not adjusted for multiple comparisons.
Results
Patient characteristics and treatment details were previously reported; 64% of the patients were men with an average age of 62 years. 1 The cohort was divided evenly between patients with stage IIIa and stage IIIb disease. Patients were followed for 0.01 to 14 years (median 6.1 years).
The . Also examined were specific AEs by organ system affected ( Table 2) .
Discussion and Conclusions
This study examined RT parameters used in LA-NSCLC cooperative group trials with the goal of determining which were associated with AEs. These data supplement our previous analysis of survival associated with similar TRT parameters.
1 Taken together, the results are helpful when choosing specific targeting strategies (IF-TRT versus ENI) and radiation doses for concurrent CRT. Our previous study examined survival and found that IF-TRT was associated with better survival than ENI was. Doses within the range used in these trials (60-74 Gy) were not associated with survival. 1 We hypothesized that the decrease in survival with ENI was due to the irradiation of more surrounding normal structures such as the heart, lungs, esophagus, bone marrow, and other immunologic tissues than IF-TRT was, thus resulting in more AEs. ENI resulted in significantly more grade 4 or higher AEs than IF-TRT did. Doses of RT higher than 60 Gy were associated with more grade 3 or higher and grade 4 or higher AEs. Importantly, grade 5 AEs plus deaths associated with therapy were more common with doses higher than 60 Gy but not with RT targeting strategy (ENI versus IF-TRT).
Three randomized CRT trials compared ENI with IF-TRT. The study by Yuan et al. included 200 patients. 2 The 2-year survival rates were significantly different (p ¼ 0.048), favoring IF-TRT. Toxicity was not different between the arms except for pneumonitis, which occurred in 29% of patients after ENI and in 17% after IF-TRT(p ¼ 0.044). Our analysis did not confirm this particular finding (see Table 2 ).
Yang et al. performed another trial; it included 55 patients who received CRT and either ENI or IF-TRT. 3 The median survival times were 15 months with IF-TRT and 13 months with ENI (p ¼ 0.084). In contrast to the present study, Yang et al. detected no differences in AEs between the treatment arms. 3 Chen et al. performed another randomized CRT trial, in which 85 patients were assigned to IF-TRT or ENI. 4 The 2-year survival rates were 53% with IF-TRT versus 35% with ENI (p ¼ 0.08). There were no differences in toxicity between the two arms. This contrasts with the present study that found more grade 4 or higher AEs with ENI.
Fernandes et al. performed a retrospective analysis of 108 patients. 5 Grade 3 or higher esophagitis developed in more patients treated with ENI than in patients treated with IF-TRT (38% versus 17% [p ¼ 0.01]). This AE, adverse event; TRT, thoracic radiotherapy; ENI, elective nodal irradiation; IF-TRT, involved-field thoracic radiotherapy; GI, gastrointestinal; Neuro, neurologic; GU, genitourinary; HEME, hematologic.
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Toxicity from Combined Modality Therapyfinding was consistent with the present study (see Table 2 ). Cooperative group trials used both IF RT and ENI, as which strategy is best was unknown. These trials were analyzed in the present pooled analysis to provide objective evidence regarding AEs. Our previous analysis, which included the same cohort, found significantly better survival with IF-TRT than with ENI, but survival was not associated with dose. 1 These data provide strong evidence that IF-TRT is preferred because of its associations with better survival and less toxicity. IF-TRT avoids irradiation of large regions, thus decreasing the dose delivered to the heart, lungs, esophagus, and the immune/hematologic system. Exposure of the heart to therapeutic irradiation has been associated with severe toxicity and poorer survival. [6] [7] [8] Additionally, Jin et al. reported that more RT received by the immune system was independently associated with inferior survival of patients with LA-NSCLC. 9 Over time, more trials have been designed to include IF-TRT, owing to concerns regarding toxicity and recognizing that the survival rates in early studies using IF-TRT were favorable.
In addition to IF-TRT, the use of newer TRT technologies can reduce toxicity. Chun et al. reported significantly less severe pneumonitis with IMRT than with three-dimensional (3D) TRT. 10 Additionally, Speirs et al. reported significantly less pneumonitis and cardiac toxicity associated with IMRT than with 3D TRT. 7 Proton beam therapy (PBT) may also decrease toxicity, as was reported by Sejpal et al. 11 Rates of grade 3 or higher pneumonitis and esophagitis in the PBT group (2% and 5%, respectively) were lower than in 3D-RT group (30% and 18%, respectively) or IMRT group (9% and 44%, respectively) (p < 0.001 for all). The same institution performed a randomized phase II trial that compared 3D PBT with IMRT; however, that study did not confirm the earlier results. 12 A phase III CRT trial comparing IMRT with PBT is currently in the accrual stage.
It was hoped that higher doses of conventionally fractionated TRT would improve the survival of patients with LA-NSCLC. However, with the RT technology used in these trials (primarily 3D TRT), escalation of total dose alone increased AEs without improving survival. 6 It is possible that altered fractionation programs using either multiple daily fractions or fewer larger fractions will improve survival without undue toxicity. 13 Regimens including multiple daily doses of TRT were found to positively affect survival at the cost of increased AEs. 14 Strengths of the present study are the large size of the cohort (N ¼ 3600) and the prospective nature of the trials. Limitations include the retrospective nature of this analysis. The use of IF RT was most common in the modern series, and improvements in supportive care over time may have also influenced outcomes. We did not compare intensity-modulated RT (IMRT) with 3D TRT, as IMRT was used in some of the patients in a single trial. Although 550 patients did have PET scans, there were no other PET data within our database and we were therefore unable to examine its potential influence on outcome. PET was required in one trial, CALGB-30407, and although not required, PET was performed in 449 patients (91%) participating in RTOG-0617. There were no tumor size or dose-volume histogram data to correlate with AEs. Although these trials included dose constraints, it would have been helpful to have had dose-volume histogram data to correlate with AEs. Advances in imaging have contributed to increasingly accurate staging and treatment planning allowing for smaller, more precise IF-TRT. Additionally, we lacked specific data regarding lymphopenia, which may be important in the immunologic effects of therapy.
This pooled analysis of AEs after CRT supplements the findings of our previous study that focused on survival. 1 In conclusion, taken together, these pooled analyses of 3600 patients with LA-NSCLC treated with concurrent CRT found that IF-TRT was associated with significantly fewer grade 4 or higher AEs and better survival than ENI was. 1 This was possible with innovations in imaging and treatment planning that generate smaller fields covering only radiographically apparent disease while sparing the adjacent normal tissues to a greater extent than was previously possible. In contrast, the use of higher total doses (>60 Gy) was associated with more severe AEs but not with improved survival. Therefore, the use of IF-TRT and 60 Gy in 2-Gy daily fractions should remain the standard of care for CRT of LA-NSCLC. Future progress in the treatment of LA-NSCLC is dependent on research improving systemic therapy, imaging, and TRT.
